Skip to main content
Erschienen in: Die Onkologie 1/2021

11.12.2020 | Knochentumoren | CME

Osteosarkom – Diagnostik, Therapie, Prognose

verfasst von: PD Dr. med. Per-Ulf Tunn, Dr. med. Manoj Kakkassery, PD Dr. med. Peter Reichardt

Erschienen in: Die Onkologie | Ausgabe 1/2021

Einloggen, um Zugang zu erhalten

Zusammenfassung

Das Osteosarkom ist der häufigste primäre maligne Knochentumor und tritt vorwiegend bei Jugendlichen im Bereich der Metaphyse der langen Röhrenknochen auf. Ein zweiter Altersgipfel liegt zwischen der sechsten und siebten Lebensdekade. Primäre Symptome sind Schwellung, Schmerzen und Funktionseinschränkung der betroffenen Körperregion innerhalb weniger Wochen. Die Röntgenuntersuchung ist die primäre Bildgebung. Bei Verdacht auf einen primären malignen Knochentumor ist die Vorstellung in einem spezialisierten Zentrum zur Komplettierung des Stagings und der Diagnosesicherung obligat. Die Behandlung erfolgt interdisziplinär und wird mit einer neoadjuvanten Chemotherapie eingeleitet, gefolgt von der operativen Therapie des Primärtumors und einer adjuvanten Chemotherapie. Die 5‑Jahres-Überlebensrate bei lokalisierter Erkrankung liegt zwischen 60 und 70 %. Eine posttherapeutische Nachsorge dient neben der Erfassung von Rezidiven der Erkennung und Behandlung von therapieinduzierten Komplikationen und Nebenwirkungen.
Literatur
1.
Zurück zum Zitat Bielack S, Kempf-Bielack B, Delling G et al (2002) Prognostic factors in high-grade osteosarcoma of the extremities or trunk. An analysis of 1702 patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols. J Clin Oncol 20:776–790CrossRef Bielack S, Kempf-Bielack B, Delling G et al (2002) Prognostic factors in high-grade osteosarcoma of the extremities or trunk. An analysis of 1702 patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols. J Clin Oncol 20:776–790CrossRef
2.
Zurück zum Zitat Kelley LM, Schlegel M, Hecker-Nolting S et al (2020) Pathological fracture and prognosis of high-grade osteosarcoma of the extremities: an analysis of 2,847 consecutive cooperative osteosarcoma study group (COSS) patients. J Clin Oncol 38(8):823–833CrossRef Kelley LM, Schlegel M, Hecker-Nolting S et al (2020) Pathological fracture and prognosis of high-grade osteosarcoma of the extremities: an analysis of 2,847 consecutive cooperative osteosarcoma study group (COSS) patients. J Clin Oncol 38(8):823–833CrossRef
3.
Zurück zum Zitat Lohmann DR (1999) RB1 gene mutations in retinoblastoma. Hum Mutat 14:283–288CrossRef Lohmann DR (1999) RB1 gene mutations in retinoblastoma. Hum Mutat 14:283–288CrossRef
4.
Zurück zum Zitat Fox MG, Trotta BM (2013) Osteosarcoma: review of the various types with emphasis on recent advancements in imaging. Semin Musculoskelet Radiol 17(2):123–136CrossRef Fox MG, Trotta BM (2013) Osteosarcoma: review of the various types with emphasis on recent advancements in imaging. Semin Musculoskelet Radiol 17(2):123–136CrossRef
5.
Zurück zum Zitat Lodwick GS, Wilson AJ, Farrell C et al (1980) Determining growth rates of focal lesions of bone from radiographs. Radiology 134(3):577–583CrossRef Lodwick GS, Wilson AJ, Farrell C et al (1980) Determining growth rates of focal lesions of bone from radiographs. Radiology 134(3):577–583CrossRef
6.
Zurück zum Zitat Lalam R, Bloem JL, Noebauer-Huhmann IM et al (2017) ESSR consensus document for detection, characterization, and referral pathway for tumors and tumorlike lesions of Bone. Semin Musculoskelet Radiol 21(5):630–647CrossRef Lalam R, Bloem JL, Noebauer-Huhmann IM et al (2017) ESSR consensus document for detection, characterization, and referral pathway for tumors and tumorlike lesions of Bone. Semin Musculoskelet Radiol 21(5):630–647CrossRef
7.
Zurück zum Zitat Liu PT, Valadez SD, Chivers SF et al (2007) Anatomically based guidelines for core needle biopsy of bone tumors: implications for limb-sparing surgery. Radiographics 27(1):189–205CrossRef Liu PT, Valadez SD, Chivers SF et al (2007) Anatomically based guidelines for core needle biopsy of bone tumors: implications for limb-sparing surgery. Radiographics 27(1):189–205CrossRef
8.
Zurück zum Zitat Franzius C, Daldrup-Link HE, Sciuk J et al (2001) FDG-PET for detection of pulmonary metastases from malignant primary bone tumors: comparison with spiral CT. Ann Oncol 12:479–486CrossRef Franzius C, Daldrup-Link HE, Sciuk J et al (2001) FDG-PET for detection of pulmonary metastases from malignant primary bone tumors: comparison with spiral CT. Ann Oncol 12:479–486CrossRef
9.
Zurück zum Zitat Franzius C, Sciuk J, Daldrup-Link HE et al (2000) FDG-PET for detection of osseous metastases from malignant primary bone tumours: comparison with bone scintigraphy. Eur J Nucl Med 27:1305–1311CrossRef Franzius C, Sciuk J, Daldrup-Link HE et al (2000) FDG-PET for detection of osseous metastases from malignant primary bone tumours: comparison with bone scintigraphy. Eur J Nucl Med 27:1305–1311CrossRef
10.
Zurück zum Zitat Andreou D, Bielack SS, Carrle D et al (2011) The influence of tumor- and treatment-related factors on the development of local recurrence in osteosarcoma after adequate surgery. An analysis of 1355 patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols. Ann Oncol 22(5):1228–1235CrossRef Andreou D, Bielack SS, Carrle D et al (2011) The influence of tumor- and treatment-related factors on the development of local recurrence in osteosarcoma after adequate surgery. An analysis of 1355 patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols. Ann Oncol 22(5):1228–1235CrossRef
11.
Zurück zum Zitat World Health Organization WHO, Fletcher CDM, Bridge JA, Hogendoorn PCW, Mertens F (2013) WHO Classification of Tumours of Soft Tissue and Bone. World Health Organization World Health Organization WHO, Fletcher CDM, Bridge JA, Hogendoorn PCW, Mertens F (2013) WHO Classification of Tumours of Soft Tissue and Bone. World Health Organization
12.
Zurück zum Zitat Wittekind C (2017) TNM Klassifikation maligner Tumoren. Wiley-VCH, Weinheim Wittekind C (2017) TNM Klassifikation maligner Tumoren. Wiley-VCH, Weinheim
13.
Zurück zum Zitat Meyers PA, Schwartz CL, Krailo MD et al (2008) Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival—a report from the Children’s Oncology Group. J Clin Oncol 26:633–638CrossRef Meyers PA, Schwartz CL, Krailo MD et al (2008) Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival—a report from the Children’s Oncology Group. J Clin Oncol 26:633–638CrossRef
14.
Zurück zum Zitat Bielack SS, Smeland S, Whelan JS et al (2015) Methotrexate, Doxorubicin, and Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP Alone in Patients With Resectable High-Grade Osteosarcoma and Good Histologic Response to Preoperative MAP: First Results of the EURAMOS‑1 Good Response Randomized Controlled Trial. J Clin Oncol 33:2279–2287CrossRef Bielack SS, Smeland S, Whelan JS et al (2015) Methotrexate, Doxorubicin, and Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP Alone in Patients With Resectable High-Grade Osteosarcoma and Good Histologic Response to Preoperative MAP: First Results of the EURAMOS‑1 Good Response Randomized Controlled Trial. J Clin Oncol 33:2279–2287CrossRef
15.
Zurück zum Zitat Marina NM, Smeland S, Bielack SS et al (2016) Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trial. Lancet Oncol 17:1396–1408CrossRef Marina NM, Smeland S, Bielack SS et al (2016) Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trial. Lancet Oncol 17:1396–1408CrossRef
16.
Zurück zum Zitat Meyers PA, Schwartz CL, Krailo M et al (2005) Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate. J Clin Oncol 23:2004–2011CrossRef Meyers PA, Schwartz CL, Krailo M et al (2005) Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate. J Clin Oncol 23:2004–2011CrossRef
17.
Zurück zum Zitat Ferrari S, Bielack SS, Smeland S et al (2018) EURO‑B.O.S.S.: a European study on chemotherapy in bone-sarcoma patients aged over 40: Outcome in primary high-grade osteosarcoma. Tumori 104:30–36CrossRef Ferrari S, Bielack SS, Smeland S et al (2018) EURO‑B.O.S.S.: a European study on chemotherapy in bone-sarcoma patients aged over 40: Outcome in primary high-grade osteosarcoma. Tumori 104:30–36CrossRef
18.
Zurück zum Zitat Kempf-Bielack B, Bielack S, Jürgens H et al (2005) Osteosarcoma relapse after combined modality therapy: an analysis of unselected patients in the Cooperative Osteosarcoma Study Group (COSS). J Clin Oncol 23:559–568CrossRef Kempf-Bielack B, Bielack S, Jürgens H et al (2005) Osteosarcoma relapse after combined modality therapy: an analysis of unselected patients in the Cooperative Osteosarcoma Study Group (COSS). J Clin Oncol 23:559–568CrossRef
19.
Zurück zum Zitat Gentet JC, Brunat-Mentigny M, Demaille MC et al (1997) Ifosfamide and etoposide in childhood osteosarcoma, a phase II study of the French Society of Paediatric Oncology. Eur J Cancer 33:232–233CrossRef Gentet JC, Brunat-Mentigny M, Demaille MC et al (1997) Ifosfamide and etoposide in childhood osteosarcoma, a phase II study of the French Society of Paediatric Oncology. Eur J Cancer 33:232–233CrossRef
20.
Zurück zum Zitat Duffaud F, Mir O, Boudou-Rouquette P et al (2019) Efficacy andf safety of regorafenib in adult patients with metastatic osteosarcoma: a non-comparative, randomised, double-blind, placebo-controlled, phase 2 study. Lancet Oncol 20:120–133CrossRef Duffaud F, Mir O, Boudou-Rouquette P et al (2019) Efficacy andf safety of regorafenib in adult patients with metastatic osteosarcoma: a non-comparative, randomised, double-blind, placebo-controlled, phase 2 study. Lancet Oncol 20:120–133CrossRef
21.
Zurück zum Zitat Berger M, Grignani G, Giostra A et al (2012) 153Samarium-EDTMP administration followed by hematopoietic stem cell support for bone metastases in osteosarcoma patients. Ann Oncol 23:1899–1905CrossRef Berger M, Grignani G, Giostra A et al (2012) 153Samarium-EDTMP administration followed by hematopoietic stem cell support for bone metastases in osteosarcoma patients. Ann Oncol 23:1899–1905CrossRef
22.
Zurück zum Zitat Bertrand TE, Cruz A, Binitie O et al (2016) Do surgical margins affect local recurrence and survival in extremity, nonmetastatic, high-grade osteosarcoma? Clin Orthop Relat Res 474(3):677–683CrossRef Bertrand TE, Cruz A, Binitie O et al (2016) Do surgical margins affect local recurrence and survival in extremity, nonmetastatic, high-grade osteosarcoma? Clin Orthop Relat Res 474(3):677–683CrossRef
23.
Zurück zum Zitat COSS Study Group, Kager L, Zoubek A, Dominkus M et al (2010) Osteosarcoma in very young children: experience of the Cooperative Osteosarcoma Study Group. Cancer 116(22):5316–5324CrossRef COSS Study Group, Kager L, Zoubek A, Dominkus M et al (2010) Osteosarcoma in very young children: experience of the Cooperative Osteosarcoma Study Group. Cancer 116(22):5316–5324CrossRef
24.
Zurück zum Zitat Abate ME, Longhi A, Galletti S et al (2010) Non-metastatic osteosarcoma of the extremities in children aged 5 years or younger. Pediatr Blood Cancer 55(4):652–654CrossRef Abate ME, Longhi A, Galletti S et al (2010) Non-metastatic osteosarcoma of the extremities in children aged 5 years or younger. Pediatr Blood Cancer 55(4):652–654CrossRef
25.
Zurück zum Zitat Worch J, Matthay KK, Neuhaus J et al (2010) Osteosarcoma in children 5 years of age or younger at initial diagnosis. Pediatr Blood Cancer 116(4):983–988 Worch J, Matthay KK, Neuhaus J et al (2010) Osteosarcoma in children 5 years of age or younger at initial diagnosis. Pediatr Blood Cancer 116(4):983–988
26.
Zurück zum Zitat Grimer RJ, Aydin BK, Wafa H et al (2016) Very long-term outcomes after endoprosthetic replacement for malignant tumours of bone. Bone Joint J 98-B(6):857–864CrossRef Grimer RJ, Aydin BK, Wafa H et al (2016) Very long-term outcomes after endoprosthetic replacement for malignant tumours of bone. Bone Joint J 98-B(6):857–864CrossRef
27.
Zurück zum Zitat Frisoni T, Cevolani L, Giorgini A et al (2012) Factors affecting outcome of massive intercalary bone allografts in the treatment of tumours of the femur. J Bone Joint Surg Br 94(6):836–841CrossRef Frisoni T, Cevolani L, Giorgini A et al (2012) Factors affecting outcome of massive intercalary bone allografts in the treatment of tumours of the femur. J Bone Joint Surg Br 94(6):836–841CrossRef
29.
Zurück zum Zitat Bus MP, van de Sande MA, Taminiau AH et al (2017) Is there still a role for osteoarticular allograft reconstruction in musculoskeletal tumour surgery? a long-term follow-up study of 38 patients and systematic review of the literature. Bone Joint J 99-B(4):522–530CrossRef Bus MP, van de Sande MA, Taminiau AH et al (2017) Is there still a role for osteoarticular allograft reconstruction in musculoskeletal tumour surgery? a long-term follow-up study of 38 patients and systematic review of the literature. Bone Joint J 99-B(4):522–530CrossRef
30.
Zurück zum Zitat Campanacci DA, Dursky S, Totti F et al (2015) Osteoartikular allografts in paediatric bone tumor reconstruction of the knee. J Biol Regul Homeost Agents 29(4 Suppl):111–119PubMed Campanacci DA, Dursky S, Totti F et al (2015) Osteoartikular allografts in paediatric bone tumor reconstruction of the knee. J Biol Regul Homeost Agents 29(4 Suppl):111–119PubMed
31.
Zurück zum Zitat Ahmed G, Zamzam M, Kamel A et al (2019) Effect of timing of pulmonary metastasis occurrence on the outcome of metastasectomy in osteosarcoma patients. J Pediatr Surg 54(4):775–779CrossRef Ahmed G, Zamzam M, Kamel A et al (2019) Effect of timing of pulmonary metastasis occurrence on the outcome of metastasectomy in osteosarcoma patients. J Pediatr Surg 54(4):775–779CrossRef
Metadaten
Titel
Osteosarkom – Diagnostik, Therapie, Prognose
verfasst von
PD Dr. med. Per-Ulf Tunn
Dr. med. Manoj Kakkassery
PD Dr. med. Peter Reichardt
Publikationsdatum
11.12.2020
Verlag
Springer Medizin
Erschienen in
Die Onkologie / Ausgabe 1/2021
Print ISSN: 2731-7226
Elektronische ISSN: 2731-7234
DOI
https://doi.org/10.1007/s00761-020-00874-8

Weitere Artikel der Ausgabe 1/2021

Die Onkologie 1/2021 Zur Ausgabe

Einführung zum Thema

Hodentumoren

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.